Effects of somatostatin analogs on glucose homeostasis in rats
Open Access
- 10 October 2011
- journal article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 212 (1), 49-60
- https://doi.org/10.1530/joe-11-0224
Abstract
Pasireotide (SOM230) is a multireceptor-targeted somatostatin analog with high binding affinity for sstr1,2,3 and sstr5. The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination. Single-dose s.c. pasireotide acutely elevated plasma glucose, whereas single-dose s.c. octreotide had no or a small hypoglycemic effect. Glucose elevation with s.c. pasireotide was transient with tachyphylaxis after repeated or continuous administration. Pasireotide and octreotide caused similar inhibitory effects on insulin secretion, whereas pasireotide had a weaker inhibitory effect on glucagon secretion than octreotide. Continuous infusion of pasireotide or injection of pasireotide long-acting release (LAR) resulted in only small and transient elevations of plasma glucose. Based on these results, and differences in the sstr binding affinity of pasireotide vs octreotide, it was hypothesized that the sstr5 vs sstr2 receptor activation ratio is the main driver of hyperglycemia after pasireotide. The results also suggest that stronger activation of sstr2 may counteract the hyperglycemic effect. Indeed, co-administration of octreotide, which has a high affinity for sstr2, with a hyperglycemic dose of pasireotide did not cause significant changes in plasma glucose levels. In conclusion, although pasireotide and octreotide inhibited insulin to a similar degree, only pasireotide administration was associated with hyperglycemia. The strong glucagon inhibitory effect exhibited by octreotide but not pasireotide may explain this observation. The lack of hyperglycemia during co-administration of pasireotide and octreotide may be explained by the greater activation of sstr2 compared with pasireotide alone, causing the insulin–glucagon balance to shift within the normoglycemic range. Extrapolation of these data to humans must account for species differences in islet cell sstr expression.Keywords
This publication has 29 references indexed in Scilit:
- Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature reviewPituitary, 2010
- Somatostatin Secreted by Islet δ-Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet FunctionDiabetes, 2009
- Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II TrialJournal of Clinical Endocrinology & Metabolism, 2009
- The role of gut hormones in glucose homeostasisJCI Insight, 2007
- Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to PegvisomantJournal of Clinical Endocrinology & Metabolism, 2005
- Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegalyClinical Pharmacology & Therapeutics, 2005
- Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatmentClinical Endocrinology, 2003
- The Pathophysiological Consequences of Somatostatin Receptor Internalization and ResistanceEndocrine Reviews, 2003
- Insulin secretion is inhibited by subtype five somatostatin receptor in the mouseSurgery, 1998
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973